Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2020 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Elapegademase.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 32697455 Free Books & Documents. Review.
No information is available on the use of elapegademase during breastfeeding. Because elapegademase is a large protein molecule with a molecular weight of about 113,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed i …
No information is available on the use of elapegademase during breastfeeding. Because elapegademase is a large protein molecul …
Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.
Onodera M, Uchiyama T, Ariga T, Yamada M, Miyamura T, Arizono H, Morio T. Onodera M, et al. Immun Inflamm Dis. 2023 Jul;11(7):e917. doi: 10.1002/iid3.917. Immun Inflamm Dis. 2023. PMID: 37506145 Free PMC article. Review.
One infant patient died of pneumonia caused by cytomegalovirus infection whereas the other three completed the study and have been observed in the study period over 3 years. The infant patient had received elapegademase at 0.4 mg/kg/week until decease and the others receiv …
One infant patient died of pneumonia caused by cytomegalovirus infection whereas the other three completed the study and have been observed …
Comparison of elapegademase and pegademase in ADA-deficient patients and mice.
Murguia-Favela L, Min W, Loves R, Leon-Ponte M, Grunebaum E. Murguia-Favela L, et al. Clin Exp Immunol. 2020 May;200(2):176-184. doi: 10.1111/cei.13420. Epub 2020 Feb 9. Clin Exp Immunol. 2020. PMID: 31989577 Free PMC article.
ADAGEN was recently replaced by a PEGylated recombinant bovine ADA, expressed in Escherichia coli (elapegademase, ELA-ADA). Limited information on ELA-ADA is available. ...
ADAGEN was recently replaced by a PEGylated recombinant bovine ADA, expressed in Escherichia coli (elapegademase, ELA-ADA). Limited i …
Long-Term Immune Reconstitution in ADA-Deficient Patients Treated With Elapegademase: A Real-World Experience.
Murguia-Favela L, Suresh S, Wright NAM, Alvi S, Tehseen S, Hernandez-Trujillo V, Seroogy CM, Haddad E, Nieves D, Hershfield MS, Walter JE, Pettiford L, Kamani NR, Keller MD, Pham-Huy A, Grunebaum E. Murguia-Favela L, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1725-1733. doi: 10.1016/j.jaip.2023.01.028. Epub 2023 Feb 1. J Allergy Clin Immunol Pract. 2023. PMID: 36736953
BACKGROUND: ADAGEN, a bovine-based enzyme replacement therapy (ERT), has been used to treat adenosine deaminase severe combined immunodeficiency (ADA-SCID). In 2018, ADAGEN was replaced by REVCOVI (elapegademase), a modified bovine recombinant protein. OBJECTIVE: To determ …
BACKGROUND: ADAGEN, a bovine-based enzyme replacement therapy (ERT), has been used to treat adenosine deaminase severe combined immunodefici …
PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
Dorsey MJ, Rubinstein A, Lehman H, Fausnight T, Wiley JM, Haddad E. Dorsey MJ, et al. J Clin Immunol. 2023 Jul;43(5):951-964. doi: 10.1007/s10875-022-01426-y. Epub 2023 Feb 25. J Clin Immunol. 2023. PMID: 36840835 Free PMC article.
This study was a 1-way crossover from pegademase to elapegademase in 7 patients with ADA-SCID to assess efficacy and safety outcomes for elapegademase. ...The 6 remaining patients completed 71-216 weeks of elapegademase therapy with a formulation that did not …
This study was a 1-way crossover from pegademase to elapegademase in 7 patients with ADA-SCID to assess efficacy and safety outcomes …